These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38872758)

  • 1. Aldosterone synthase inhibitor "Baxdrostat" for resistant hypertension: A clinical approach or futuristic idea?
    Siddiqui MO; Qureshi AA; Siddiqui A; Ain NU
    Chronic Dis Transl Med; 2024 Jun; 10(2):146-148. PubMed ID: 38872758
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension.
    Dey S; Frishman WH; Aronow WS
    Cardiol Rev; 2023 Aug; ():. PubMed ID: 37548462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
    Freeman MW; Halvorsen YD; Marshall W; Pater M; Isaacsohn J; Pearce C; Murphy B; Alp N; Srivastava A; Bhatt DL; Brown MJ;
    N Engl J Med; 2023 Feb; 388(5):395-405. PubMed ID: 36342143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
    Forzano I; Mone P; Varzideh F; Jankauskas SS; Kansakar U; De Luca A; Santulli G
    Front Endocrinol (Lausanne); 2022; 13():1097968. PubMed ID: 36568122
    [No Abstract]   [Full Text] [Related]  

  • 7. Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease.
    Awosika A; Khan A; Adabanya U; Omole AE; Millis RM
    Cureus; 2023 Mar; 15(3):e36184. PubMed ID: 36937127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function.
    Freeman MW; Halvorsen YD; Bond M; Murphy B; Isaacsohn J
    Clin Pharmacol Drug Dev; 2024 Apr; 13(4):410-418. PubMed ID: 38311833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Am J Cardiovasc Drugs; 2023 May; 23(3):277-286. PubMed ID: 36790596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
    Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
    Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New trials in resistant hypertension: mixed blessing stories.
    Zoccali C; Mallamaci F; De Nicola L; Minutolo R
    Clin Kidney J; 2024 Jan; 17(1):sfad251. PubMed ID: 38186891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    J Clin Endocrinol Metab; 2023 Jul; 108(8):e638-e639. PubMed ID: 36740773
    [No Abstract]   [Full Text] [Related]  

  • 13. Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors.
    Feldman JM; Frishman WH; Aronow WS
    Cardiol Rev; 2024 Feb; ():. PubMed ID: 38358268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
    Ando H
    Hypertens Res; 2023 Apr; 46(4):1056-1057. PubMed ID: 36653520
    [No Abstract]   [Full Text] [Related]  

  • 15. Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation.
    Azzam O; Nejad SH; Carnagarin R; Nolde JM; Galindo-Kiuchi M; Schlaich MP
    Br J Pharmacol; 2024 Feb; 181(3):319-339. PubMed ID: 37715452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revising the Roles of Aldosterone in Vascular Physiology and Pathophysiology: From Electocortin to Baxdrostat.
    Feldman RD; Sanjanwala R; Padwal R; Leung AA
    Can J Cardiol; 2023 Dec; 39(12):1808-1815. PubMed ID: 37734710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach.
    Nardoianni G; Pala B; Scoccia A; Volpe M; Barbato E; Tocci G
    High Blood Press Cardiovasc Prev; 2024 Mar; 31(2):99-112. PubMed ID: 38616212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of resistant hypertension.
    Camafort M; Kreutz R; Cho MC
    Heart; 2023 Dec; ():. PubMed ID: 38135468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment.
    Guo C; Zhang G; Wu C; Lei Y; Wang Y; Yang J
    Eur J Med Chem; 2024 Aug; 274():116521. PubMed ID: 38820853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.